Valuation dashboard for ADMA Biologics, Inc. (ADMA) with P/E 12.55, P/B 5.05, EV/EBITDA 21.93 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally.
Analysis Summary
ADMA Biologics, Inc. reported revenue of $510.2M in the most recent fiscal year, growing at a 5-year CAGR of 64.6%.
Trailing-twelve-month margins: gross margin 64.7%, operating margin 42.3%, net margin 33.0%.
At the current price of $8.90, ADMA trades at a P/E of 12.55 and an ROE of 30.78%. Market capitalisation stands at $2.1B.
Balance sheet quality for ADMA: current ratio of 6.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 12.55 |
| Price / Book | 5.05 |
| EV / EBITDA | 21.93 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-111.57 |
| vs Current Price | -1353.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADMA | ADMA Biologics, Inc. | $2.1B | 12.55 | 5.05 | 30.8% |
| BLTE | Belite Bio, Inc | $6.8B | 8.75 | -10.1% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.7B | 6.80 | -34.1% | |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | -410.2% | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.7B | 27.49 | 5.71 | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.8B | 12.10 | 3.57 | 32.4% |
| DYN | Dyne Therapeutics, Inc. | $3.4B | 4.20 | -64.3% |
Price
| Price | $8.90 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 30.78% |
| Return on Invested Capital | 27.57% |
| Return on Assets | 23.54% |
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Net Margin | 32.98% |
Related companies: ACAD · BLTE · CRNX · DYN · LGND · MIRM · PRAX
Explore sector: Healthcare · Biotechnology
More sections of ADMA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks